Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuterol Spiromax Dose Counter Assessment
NCT01857323Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2013
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of albuterol spiromax in asthma, chronic obstructive pulmonary disease (COPD), sponsored by Teva Pharmaceutical Industries Ltd.. Started May 2013; status: completed.
02
Drugs
albuterol spiromax
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01857323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01857323.